Aktien Sensor

AbbVie Inc. has acquired Capstan Therapeutics in a $2.1 billion deal, expanding its autoimmune portfolio and access to in vivo cell therapy technology.

UnitedHealth Group’s stock price has surged due to a multi-year agreement with Memorial Sloan Kettering Cancer Center, alleviating concerns over cancer treatment disruptions.

Agilent Technologies Inc.’s stock price has risen to a new high due to the growing demand for in vitro diagnostics, driven by factors such as chronic disease prevalence and advancements in molecular diagnostics.

IQVIA Holdings Inc is navigating the dynamic healthcare industry with ease, leveraging AI and strategic partnerships to drive growth and capitalize on emerging trends.

QIAGEN NV is well-positioned to capitalize on growth trends in the In Vitro Diagnostics and metagenomics markets, driven by increasing demand for diagnostic solutions and decreasing sequencing costs.

Biogen has initiated a Phase 3 study to evaluate its investigational drug felzartamab for treating primary membranous nephropathy, a rare and debilitating kidney disease.

Alnylam Pharmaceuticals’ stock price has reached an all-time high, driven by the company’s commitment to innovation and its groundbreaking approach to developing treatments for human diseases.

Align Technology’s stock price has seen a significant shift, dropping from a 52-week high of $263.24 to a current price of $189.33, leaving investors and analysts wondering what’s behind the decline.

Haleon has strengthened its research and development leadership by appointing Carl Haney as its new Chief R&D Officer, amidst a stable share performance.

Teva Pharmaceutical’s stock price has plummeted, but the company is attempting to recover through innovation and research, including a new startup challenge program and focus on developing new treatments.